1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Zeria Pharmaceutical Co., Ltd.

Zeria Pharmaceutical Co., Ltd.

4559.T
Zeria Pharmaceutical Co., Ltd.JP flagTokyo Stock Exchange
2,095.00
JPY
+28.00
- -
92.35BMarket Cap
Zeria Pharmaceutical Co., Ltd.
4559.T
(Tokyo Stock Exchange)

Recent

price

2,095.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
1,088.31
1,169.52
1,172.59
1,351.05
1,149.57
1,176.28
1,221.12
1,253.76
1,245.06
1,293.73
1,145.11
1,318.88
1,548.07
1,717.89
1,980.78
2,022.69
885.82
Revenue per Share
40.5
62.9
87.57
115.01
48.15
66.15
66.73
80.72
69.56
62.62
68.22
87.76
140.26
175.39
225.42
191.8
52.96
Basic EPS, GAAP
84.73
101.88
49.72
73.68
-23.05
-437.78
66.2
131.61
80.21
127.97
-200.52
166.83
237.69
187.95
231.13
160.16
- -
Free Cash Flow per Basic Share
15.4
18.99
22.64
25.11
29.86
29.89
31.9
33.22
34.28
34.2
34.03
34.08
35.99
43.91
44.85
47.85
- -
Dividend per Share
708.85
752.86
817.83
900.34
809.27
835.98
870.72
945.29
1,015.31
1,100.87
1,149.23
1,228.52
1,359.55
1,493.81
1,674.27
1,818.06
1,609.34
Book Value per Share
318.57
382.26
534.09
991.27
945.59
532.5
557.65
647.65
595.07
488.73
305.67
307.64
537.66
832.32
1,121.51
1,565.88
1,004.55
Tangible Book Value per Share
45
45
45
46
53
53
53
52
50
47
46
45
44
44
44
44
44
Basic Weighted Avg Shares
49,514
53,194
53,325
61,992
61,061
62,479
64,860
64,578
61,824
60,435
52,757
59,533
68,383
75,725
87,311
89,159
39,047
Sales/Revenue/Turnover
6.69
8.59
8.65
10.95
4.39
7.31
7
7.48
6.04
6.78
6.59
10.69
13.18
12.71
13.97
13.88
11
Operating Margin (%)
2,873
3,165
2,837
2,625
2,706
3,119
3,795
3,840
3,734
3,944
4,436
5,401
6,148
7,555
7,555
7,347
- -
Depreciation Expense
1,843
2,861
3,982
5,277
2,558
3,513
3,544
4,158
3,454
2,925
3,143
3,961
6,196
7,731
9,936
8,455
2,334
Net Income, GAAP
33.61
37.7
33.64
27.84
33.04
32.87
27.33
25
33.66
25.04
20.26
30.53
14.66
19.07
21.01
24.85
26.11
Effective Tax Rate (%)
3.72
5.38
7.47
8.51
4.19
5.62
5.46
6.44
5.59
4.84
5.96
6.65
9.06
10.21
11.38
9.48
5.98
Profit Margin (%)
-4,823
2,397
5,409
23,949
23,770
-8,550
-6,413
2,346
-115
-6,050
-16,483
-2,529
1,045
3,291
15,081
26,939
10,594
Working Capital
14,582
19,123
15,666
13,867
10,636
4,654
2,884
8,676
7,796
5,471
5,820
18,386
14,541
7,944
6,866
5,270
7,336
LT Debt
28,424
30,495
36,910
58,735
62,571
64,067
63,505
65,696
59,348
52,679
56,153
55,092
65,681
79,829
89,797
108,605
88,568
Total Equity
3.49
4.34
4.52
6.26
2.07
3.16
3.17
3.62
2.53
3.34
2.85
4.12
6.88
6.39
7.33
6.47
2.42
Return on Invested Capital (%)
3.11
4.38
6.08
8.02
4.05
4.8
4.34
5.19
4.24
3.56
3.5
3.95
5.95
7.33
9.02
7.56
2.23
Return on Capital (%)
5.82
8.61
11.15
13.44
6.07
8.04
7.82
8.76
6.97
5.74
6.02
7.31
10.73
12.28
14.23
10.98
3.45
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
38,284
- -
35,181
LT Borrowings
7,944
- -
7,336
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
44
- -
44
Market Capitalization
93,979
93,140
100,061

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
57,809
- -
64,644
Cash, Cash Equivalents & STI
20,324
- -
24,361
Accounts Receivable, Net
21,249
- -
23,888
Inventories
14,490
- -
15,036
Total Current Liabilities
54,518
- -
54,050
Payables & Accruals
- -
- -
- -
ST Debt
38,284
- -
35,181
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.06%
14.46%
20.94%
Free Cash Flow
-43.89%
-34.18%
-30.7%
Net Income, GAAP
11.42%
24.17%
-14.91%
Sales/Revenue/Turnover
4%
11.17%
2.12%
Total Cash Common Dividend
3.13%
6.41%
6.71%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
18,305
18,374
21,241
17,806
75,725
2025
- -
- -
- -
- -
87,311
2026
- -
- -
- -
- -
89,159

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
66.14
- -
- -
- -
175.39
2025
- -
- -
- -
- -
225.42
2026
- -
- -
- -
- -
191.8

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
43.91
2025
- -
- -
- -
- -
44.85
2026
- -
- -
- -
- -
47.85
Similar Companies
TransCanna Holdings Inc. (TCNAF)
Malin Corporation plc (MLC.IR)
Hikma Pharmaceuticals PLC (HIK.L)
Jilin Province Huinan Changlong Bio-pharmacy Company Limited (8049.HK)
Revive Therapeutics Ltd. (RVVTF)
Strides Pharma Science Limited (STAR.BO)
Business
Zeria Pharmaceutical Co., Ltd. (4559.T) manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents; cosmetics; health foods; alcoholic beverages; soft drinks; food additives; livestock feed; hygienic goods; medical devices; health equipment; hygiene facilities and equipment; beauty appliances; and measuring and analytical equipment. The company, founded in December 1955 and headquartered in Tokyo, Japan, specializes in ethical drugs primarily for gastroenterology including therapeutic agents for functional dyspepsia (Acofide), ulcerative colitis and Crohn's disease (Asacol), gastritis and ulcers (Promac), oral bowel cleansing agents (Visiclear), laxatives (WithOne), hypophosphatemia (Phosribbon), iron deficiency anemia (Ferinject), hyperkalemia (Veltassa), and proton pump inhibitors; long-acting calcium channel blockers (Landel); oral NSAIDs (Peon); anti-leukopenia products (Ancer); anti-inflammatory topical agents; non-steroidal anti-inflammatory ophthalmic solutions; zinc-containing anti-ulcerants; consumer healthcare products such as nutritional health drugs (Hepalyse, Chondroitin ZS Tablets), gastrointestinal remedies (Acinon Z, Stomacool), western herbal medicines, cold remedies (Cepie), ophthalmic solutions (Viewclear, AZ), anti-inflammatory/analgesics (ESBIEN S), hemorrhoidal remedies, dermal remedies (Aposty, Dolmycin), quasi-drugs/cosmetics, nutrient tonics, soft drinks/health foods, and foods for specified health uses; as well as beverages like Hepalyse W series. Zeria operates production facilities in Japan (Saitama, Tsukuba, 2nd Tsukuba, IONA's Fukushima), Switzerland (Tillotts Pharma's Ziefen), Denmark (ZPD's Esbjerg), and Vietnam (F.T. Pharma's Cat Lai), with international subsidiaries including Tillotts Pharma AG (Switzerland, gastroenterology focus), ZPD A/S (Denmark), and presence in Europe (Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy), Vietnam, and Denmark targeting healthcare professionals, patients, and consumers primarily in gastroenterology, orthopedics, dermatology, and consumer health segments. Recent developments include the merger with subsidiary Kenso-Seiyaku in April 2025; launch of Veltassa 8.4g powder for suspension for hyperkalemia in March 2025 and Hepalyse W Shine beverage in October 2024; partnership between Tillotts Pharma and Pioneer Pharmaceuticals for marketing and distribution of Asacol Tablets 800mg in China announced in late 2024; agreement with Agastra-Lab for development of Acotiamide in 2024; takeover of manufacturing and marketing approval for Dafclear Tablets (fidaxomicin) from Astellas Pharma in April 2023; and formation of JoinHealth ApS by ZPD A/S and EHP ApS.